Literature DB >> 19170679

Reduced plasma fibrinolytic capacity as a potential risk factor for a first myocardial infarction in young men.

Mirjam E Meltzer1, Carine J M Doggen, Philip G de Groot, Frits R Rosendaal, Ton Lisman.   

Abstract

Studies on the relationship between fibrinolysis and arterial thrombosis have been conflicting. Previously, we demonstrated that hypofibrinolysis, as measured by a plasma-based assay, increased the risk of venous thrombosis. The present study investigated increased clot lysis time (CLT) measured with the same assay as a risk factor for myocardial infarction in a case-control study including 421 men with a first myocardial infarction and 642 controls below 70 years. CLT was strongly associated with body-mass index, lipid levels, blood pressure and C-reactive protein. Overall, risk of myocardial infarction was 1.4-fold (95% confidence interval (CI) 1.0-1.9) increased for CLT in the fourth quartile (longest CLT) compared with the first quartile. After adjusting for cardiovascular risk factors this risk disappeared (OR 1.0, 95%CI 0.6-1.5). In men aged <50 years the association was pronounced (OR 3.2, 95%CI 1.5-6.7). After adjustment for cardiovascular risk factors the risk was nearly twofold increased (OR 1.8, 95%CI 0.7-4.8). In men aged > or = 50 years, no clear association between CLT and risk of myocardial infarction was found. Our study suggests that hypofibrinolysis increases the risk of a first myocardial infarction in young men, although the causality of this association remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19170679     DOI: 10.1111/j.1365-2141.2008.07569.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  Genome scan of clot lysis time and its association with thrombosis in a protein C-deficient kindred.

Authors:  M E Meltzer; S J Hasstedt; C Y Vossen; P W Callas; Ph G DE Groot; F R Rosendaal; T Lisman; E G Bovill
Journal:  J Thromb Haemost       Date:  2011-07       Impact factor: 5.824

Review 2.  Fibrinolysis and the control of blood coagulation.

Authors:  John C Chapin; Katherine A Hajjar
Journal:  Blood Rev       Date:  2014-09-16       Impact factor: 8.250

3.  Fibrinolytic Activity of Blood and its Determinants in Healthy Medical Students.

Authors:  Nazeem I Siddqui; M Shoeb; S Bose
Journal:  J Clin Diagn Res       Date:  2015-06-01

4.  The fibrinogen γA/γ' isoform does not promote acute arterial thrombosis in mice.

Authors:  B L Walton; T M Getz; W Bergmeier; F-C Lin; S Uitte de Willige; A S Wolberg
Journal:  J Thromb Haemost       Date:  2014-05       Impact factor: 5.824

5.  Plasma clot lysis time and its association with cardiovascular risk factors in black Africans.

Authors:  Zelda de Lange; Marlien Pieters; Johann C Jerling; Annamarie Kruger; Dingeman C Rijken
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

6.  Low fasting glucose is associated with enhanced thrombin generation and unfavorable fibrin clot properties in type 2 diabetic patients with high cardiovascular risk.

Authors:  Grzegorz Gajos; Malgorzata Konieczynska; Jaroslaw Zalewski; Anetta Undas
Journal:  Cardiovasc Diabetol       Date:  2015-05-01       Impact factor: 9.951

Review 7.  Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk.

Authors:  Katherine Kearney; Darren Tomlinson; Kerrie Smith; Ramzi Ajjan
Journal:  Cardiovasc Diabetol       Date:  2017-03-09       Impact factor: 9.951

8.  Patho- physiological role of BDNF in fibrin clotting.

Authors:  Patrizia Amadio; Benedetta Porro; Leonardo Sandrini; Susanna Fiorelli; Alice Bonomi; Viviana Cavalca; Marta Brambilla; Marina Camera; Fabrizio Veglia; Elena Tremoli; Silvia S Barbieri
Journal:  Sci Rep       Date:  2019-01-23       Impact factor: 4.379

Review 9.  Hypofibrinolysis in type 2 diabetes and its clinical implications: from mechanisms to pharmacological modulation.

Authors:  Agata Hanna Bryk-Wiązania; Anetta Undas
Journal:  Cardiovasc Diabetol       Date:  2021-09-22       Impact factor: 9.951

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.